SPONSOR INFORMATION

Our Open Trials

Pivotal

Randomized Withdrawal

Open Safety

Pivotal

Randomized Withdrawal

Open Safety

Extended Safety


10 week, double-blind

Pivotal

Randomized Withdrawal

Open Safety

Extended Safety


3 week, double-blind


2 year, randomized withdrawal


12 month, open-label safety

Pivotal

Randomized Withdrawal

Open Safety

Extended Safety


8 week, double-blind


3 year, open-label safety

Pivotal

Randomized Withdrawal

Open Safety

Extended Safety


7 week, double-blind


3 year, open-label safety

Our Upcoming Trials

Phase III Adult Adjunctive Major Depressive Disorder,
1 year, randomized withdrawal

Phase III Adult Major Depressive Disorder,
12 week, double-blind

Phase III Adult Major Depressive Disorder,
1 year, open-label extension

Our Completed Trials

Major Depressive Disorder

7 adult adjunctive MDD trials
3 adult monotherapy MDD trials
1 adolescent monotherapy MDD trial
1 elderly treatment-resistant MDD trial

Substance Use Disorders

1 adolescent nicotine use disorder trial
3 adult opioid use disorder trials

▾ All Completed Substance Use Disorder Studies

Phase III Adolescent Nicotine Use Disorder,
52 week, double-blind.

Phase III Adult Opioid Use Disorder,
29 week, double-blind.

Phase III Adult Opioid Use Disorder,
6/12 month, open-label extension and open-label de novo.

Phase III Adult Opioid Use Disorder,
6 month, open-label treatment.

Anxiety Disorder

1 adult adjunctive obsessive compulsive disorder trial

▾ All Completed Anxiety Disorder Studies

Eating Disorders

4 binge eating disorder trials

▾ All Completed Eating Disorder Studies

Phase III Adult Binge Eating Disorder,
12 week, double-blind.

Phase III Adult Binge Eating Disorder,
12 month, open-label extension.

Phase III Adult Binge Eating Disorder,
39 week, randomized withdrawal study.

Phase II Adult Binge Eating Disorder,
12 week, double-blind.

Sexual Dysfunction Disorders

2 adult hypoactive sexual desire disorder trials

▾ All Completed Sexual Dysfunction Studies

Bipolar Disorder

2 adjunctive MDD associated with bipolar I disorder trials

ENROLLMENT GOALS

Detailed enrollment figures are available upon request.